Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China’s Simcere, for €42m upfront.
Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new


